rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Praxis Precision Medicines, Inc.

PRAX · Nasdaq

Health CareBiotechnologyNot moving yet

PRAX stood above a rising 150-day average in 43 of the last 52 weekly readings, and has been out of that trend for the last 5 weeks. It is 23.8% below that average now. Biotechnology: 15% of its 561 stocks in an uptrend (−17 points in four weeks); Health Care: 25% (−11 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 5
Industry in uptrend
15% -17 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$14.7M
Officials’ trades on record
2
Institutions holding
295 (+17)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 43 of 52 weeks.

17 Apr – 16 Oct
16%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$32.0M$0Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

2 disclosed lines: House 2, Senate 0, executive 0; 1 people.

WhoDidAmountTraded
Gilbert Ray Cisneros, Jr. House: U.S. House ClerkCA31bought$1k–$15k29 Sep 2026filed 12 Oct 2026
Gilbert Ray Cisneros, Jr. House: U.S. House ClerkCA31bought$1k–$15k30 Jul 2026filed 4 Sep 2026

Insiders

Buy orders, 12 months0
Sale orders, 12 months3
Buyers · sellers0 · 3
WhoDidSharesTraded
Jill DesimoneDirectorsold10at $301.4424 Jun 2026filed 26 Jun 2026
Jill DesimoneDirectorsold120at $303.1324 Jun 2026filed 26 Jun 2026
Jill DesimoneDirectorsold320at $305.3124 Jun 2026filed 26 Jun 2026
Jill DesimoneDirectorsold683at $306.7724 Jun 2026filed 26 Jun 2026
Jill DesimoneDirectorsold1,240at $308.2424 Jun 2026filed 26 Jun 2026
Jill DesimoneDirectorsold999at $309.3824 Jun 2026filed 26 Jun 2026
Jill DesimoneDirectorsold1,750at $310.8924 Jun 2026filed 26 Jun 2026
Jill DesimoneDirectorsold2,854at $311.9124 Jun 2026filed 26 Jun 2026
Jill DesimoneDirectorsold1,004at $312.8324 Jun 2026filed 26 Jun 2026
Jill DesimoneDirectorsold504at $313.6624 Jun 2026filed 26 Jun 2026
Jill DesimoneDirectorsold1,279at $314.9024 Jun 2026filed 26 Jun 2026
Jill DesimoneDirectorsold837at $315.7124 Jun 2026filed 26 Jun 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders295+17 on the quarter
New · exited58 · 40
Reported value$11.0B

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
Jupiter Topco LLCnew · filed 14 Aug 20263,421,374$1.1B+3,421,374
FMR LLCadded · filed 13 Aug 20262,316,907$775.7M+155,964+7.2%
BlackRock, Inc.reduced · filed 7 Aug 20262,292,585$767.5M-32,344−1.4%
PERCEPTIVE ADVISORS LLCunchanged · filed 14 Aug 20262,035,986$681.6M00.0%
BAKER BROS. ADVISORS LPunchanged · filed 14 Aug 20261,753,198$587.0M00.0%
Orbis Allan Gray Ltdreduced · filed 14 Aug 20261,529,788$512.2M-942,692−38.1%
VANGUARD PORTFOLIO MANAGEMENT LLCadded · filed 13 Aug 20261,335,185$447.0M+578,437+76.4%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 20261,235,299$413.6M+13,355+1.1%
STATE STREET CORPadded · filed 7 Aug 20261,026,443$343.7M+142,205+16.1%
ADAGE CAPITAL PARTNERS GP, L.L.C.added · filed 14 Aug 20261,015,480$340.0M+199,741+24.5%
31 Dec 2023 – 30 Jun 2026
62174286Dec 23Sep 24Mar 25Dec 25Jun 26

News

No headline names it lately.

Everyone who traded it

Gilbert Ray Cisneros, Jr. HouseCA31 · last 29 Sep 20262 · 0
Marcio Souza Company insiderChief Executive Officer · last 8 Jul 20265 · 0
Jill DeSimone Company insiderDirector · last 24 Jun 20261 · 1
Dean J. Mitchell Company insiderDirector · last 10 Jun 20262 · 0
Gregory Norden Company insiderDirector · last 10 Jun 20260 · 0
Jeffrey B. Kindler Company insiderDirector · last 10 Jun 20260 · 0
Jeffrey Chodakewitz Company insiderDirector · last 10 Jun 20260 · 0
Merit Ester Cudkowicz Company insiderDirector · last 10 Jun 20260 · 0
Stuart A. Arbuckle Company insiderDirector · last 10 Jun 20260 · 0
William D. Young Company insiderDirector · last 10 Jun 20260 · 0
Alex Nemiroff Company insiderGeneral Counsel and Secretary · last 14 May 20261 · 2
Lauren Mastrocola Company insiderPrincipal Accounting Officer · last 14 May 20261 · 2

Same industry

MRNA ModernaLeading+147%
ENTX Entera BioLeading+37%
XNCR XencorLeading+30%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Return on capital employedFY 2025 · to 31 Dec 2025-37.1%
Share count trendFY 2025 · to 16 Feb 202610.5%
Cash and equivalentsFY 2025 · to 31 Dec 2025$357.3M
Free cash flowFY 2025 · to 31 Dec 2025−$249.1M

Analyst forecasts

No analyst forecasts yet.